Immunotherapy & thoracic cancers

Thoracic malignancies present a significant global health burden with the incidence and mortality of both lung cancer and malignant pleural mesothelioma (MPM) increasing by year. Lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is the leading cause of cancer-related deaths, worldwide. The incidence and mortality rates of MPM, still considered a “rare disease”, have not yet peaked but they are increasing yearly. Thymic tumors are the most common tumors in the anterior mediastinum, being part of the thoracic. Survival rates for all these cancers are poor, as the majority of patients are diagnosed with late stage disease.